Skip to content

Maximum effective volume (MEV90) of ropivacaine for intermuscular sulcus block at cervical 5 level

Maximum effective volume (MEV90) of ropivacaine for intermuscular sulcus block at cervical 5 level

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061851
Enrollment
Unknown
Registered
2022-07-04
Start date
2022-07-20
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthroscopic shoulder surgery

Interventions

1:Brachial plexus block was performed with 0.375% ropivacaine
2:The diffusion of local anesthetics containing contrast agent was observed by CT three-dimensional reconstruction.

Sponsors

The Second Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Men and women aged 18-60 years; 2. ASA: I-III, unilateral shoulder arthroscopic surgery with consent to surgery.

Exclusion criteria

Exclusion criteria: Patients with BMI > 30 kg/m2, contrast agent allergy, mental illness, chronic obstructive pulmonary disease or any respiratory disease, coagulation disorder, prior trauma, neuropathy, myopathy, and requiring open surgery were excluded from the study.

Design outcomes

Primary

MeasureTime frame
Block scope;

Secondary

MeasureTime frame
The patient first proposed the time for additional analgesic drugs and the total analgesic demand of 24h;pain score;

Countries

China

Contacts

Public ContactJiang Zhu

The Second Affiliated Hospital of Soochow University

396045663@qq.com+86 13962153438

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026